Presentation ESC 2022 Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies Presenter: Michelle L. O’Donoghue August 29, 2022 REGISTER for free or LOG IN to view this content Clinical Cardiology Clinical Pharma Presentation ESC 2022 Up Next Presentation ESC 2022 Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial Presenter: Otavio Berwanger August 29, 2022 More slides + Presentation ESC 2022 Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial Presenter: John Eikelboom August 29, 2022 Presentation ESC 2022 A Polypill Strategy in Secondary Prevention: Results of the SECURE Trial Presenter: Valentin Fuster August 29, 2022 We Recommend
Presentation ESC 2022 Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial Presenter: Otavio Berwanger August 29, 2022
Presentation ESC 2022 Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial Presenter: John Eikelboom August 29, 2022
Presentation ESC 2022 A Polypill Strategy in Secondary Prevention: Results of the SECURE Trial Presenter: Valentin Fuster August 29, 2022